Related Experiment Video
Updated: Sep 17, 2025
06:09
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
22.7K
Leucine-Rich Repeat Kinase 2: Pathways to Parkinson's Disease
Suzanne R Pfeffer1,2,3, Dario R Alessi2,3,4
1Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305-5307, USA pfeffer@stanford.edu.
Cold Spring Harbor Perspectives in Medicine
|June 30, 2025
Summary
Leucine-rich repeat kinase 2 (LRRK2) mutations drive Parkinson's disease by altering Rab protein phosphorylation. LRRK2 inhibitors show therapeutic potential by reversing downstream effects like impaired Hedgehog signaling.
Area of Science:
- Biochemistry
- Cell Biology
- Neuroscience
Background:
- Leucine-rich repeat kinase 2 (LRRK2) mutations are a significant genetic factor in Parkinson's disease (PD).
- Understanding LRRK2's kinase activity and downstream effects is crucial for PD pathogenesis and therapeutic development.
Purpose of the Study:
- To elucidate the molecular mechanisms by which LRRK2 mutations contribute to Parkinson's disease.
- To investigate the role of LRRK2 in phosphorylating Rab GTPases and its impact on cellular signaling pathways.
- To evaluate the therapeutic potential of LRRK2 inhibitors in reversing PD-associated cellular dysfunction.
Main Methods:
- Cryoelectron microscopy to determine LRRK2 structures and inhibitor binding.
- Biochemical assays to study LRRK2 membrane recruitment and Rab substrate phosphorylation.
- Cellular assays to assess the effects of LRRK2 activation on primary cilia and Hedgehog signaling.
Main Results:
- LRRK2 phosphorylates specific Rab GTPases, altering their binding partners.
- LRRK2 activation, particularly during lysosomal stress, leads to the formation of phospho-Rab-effector complexes.
- These complexes disrupt primary cilia and impair Hedgehog signaling, effects reversible by LRRK2 inhibitors.
Conclusions:
- LRRK2-mediated disruption of Hedgehog signaling provides a link between genetic and idiopathic Parkinson's disease.
- LRRK2 inhibitors demonstrate therapeutic promise for Parkinson's disease by restoring normal cellular function.
Related Concept Videos
01:15Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
01:37Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
01:19Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
01:07MAPK Signaling Cascades
6.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.2K
01:25cAMP-dependent Protein Kinase Pathways
6.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K